Section Arrow
XRTX.NASDAQ
- XORTX Therapeutics
Quotes are at least 15-min delayed:2024/05/16 00:38 EDT
Last
 2.49
+0.04 (+1.63%)
Day High 
2.6499 
Prev. Close
2.45 
1-M High
3.5499 
Volume 
12.55K 
Bid
2.35
Ask
2.8
Day Low
2.4201 
Open
2.59 
1-M Low
2.39 
Market Cap 
7.10M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.6 
20-SMA 2.74 
50-SMA 3.61 
52-W High 7.524 
52-W Low 1.98 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.60/-2.30
Enterprise Value
7.11M
Balance Sheet
Book Value Per Share
1.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 00:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.